Inhibition of HIV-1 replication by novel lentiviral vectors expressing transdominant Rev and HIV-1 env antisense
Open Access
- 1 April 2002
- journal article
- research article
- Published by Springer Nature in Gene Therapy
- Vol. 9 (7) , 421-431
- https://doi.org/10.1038/sj.gt.3301674
Abstract
Retroviral vectors expressing transdominant negative mutants of Rev (TdRev) inhibit HIV-1 replication by preventing the nuclear export of unspliced viral transcripts, thus inhibiting the synthesis of Gag-Pol, Env and reducing the levels of genomic RNA available for packaging. Due to these effective mechanisms of inhibition, production of HIV-1-based lentiviral vectors expressing TdRev has been difficult. Here we describe HIV-based vectors in which expression of TdRev is negatively regulated by Rev expression. In these vectors, we maintained the wild-type HIV-1 Tat/Rev exons and intron configuration and its mode of splicing regulation. The second Rev exon was mutated to encode TdRev. Inhibition of TdRev expression by Rev during vector production yields high titer vector preparations. A second vector containing an additional anti-HIV gene (env-antisense) was constructed by flipping a 1.2-kb env fragment contained within the Tat/TdRev intron. SupT1 cells and primary CD4+ lymphocytes transduced with these vectors inhibit HIV-1 replication and show a preferential advantage for survival. Although these vectors are poorly mobilized to secondary target cells by wild-type HIV-1, they reduce the infectivity of the wild-type virions escaping inhibition.Keywords
This publication has 34 references indexed in Scilit:
- Inhibition of Human Immunodeficiency Virus Type 1 (HIV-1) Replication by HIV-1-Based Lentivirus Vectors Expressing Transdominant RevJournal of Virology, 2001
- Efficient Gene Transfer to Human Peripheral Blood Monocyte-Derived Dendritic Cells Using Human Immunodeficiency Virus Type 1-Based Lentiviral VectorsHuman Gene Therapy, 2000
- Improved titers of HIV-based lentiviral vectors using the SRV-1 constitutive transport elementGene Therapy, 2000
- Modified Human Immunodeficiency Virus-Based Lentiviral Vectors Display Decreased Sensitivity toTrans-Dominant RevHuman Gene Therapy, 2000
- Inhibition of Human Immunodeficiency Virus Type 1 by Tat/Rev-Regulated Expression of Cytosine Deaminase, Interferon alpha2, or Diphtheria Toxin Compared with Inhibition by Transdominant RevHuman Gene Therapy, 1999
- Gene therapy targeting cord blood-derived CD34+ cells from HIV-exposed infants: preclinical studiesGene Therapy, 1998
- High transdominant RevM10 protein levels are required to inhibit HIV-1 replication in cell lines and primary T cells: implication for gene therapy of AIDSGene Therapy, 1997
- Analysis oftrans-Dominant Mutants of the HIV Type 1 Rev Protein for Their Ability to Inhibit Rev Function, HIV Type 1 Replication, and Their Use as Anti-HIV Gene TherapeuticsAIDS Research and Human Retroviruses, 1995
- Inhibition of Human Immunodeficiency Virus Type-1 by Retroviral Vectors Expressing Antisense-TARHuman Gene Therapy, 1994
- Transfer of an Anti-HIV-1 Ribozyme Gene into Primary Human LymphocytesHuman Gene Therapy, 1994